ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies
In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop a Parsortix-based Androgen Receptor (AR) detection assay for prostate cancer studies. The assay will be developed in ANGLE’s UK laboratories, and its successful implementation could pave the way for long-term clinical study collaboration.
Key Points:
1. The new AR detection assay will be created using the Parsortix system, highlighting its potential in assessing prostate cancer therapeutics.
2. ANGLE aims to complete the project by Q1 2025, demonstrating the assay’s value in minimally invasive AR assessment.
3. The deal follows a previous collaboration to develop CTC micronuclei detection using ANGLE’s DNA Damage Response assay.
ANGLE plc secures £550,000 deal with AstraZeneca to develop Parsortix-based Androgen Receptor detection assay, enhancing CTC prostate cancer research.
Details of the Agreement:
The assay will allow researchers to conduct longitudinal, non-invasive assessments of AR status throughout clinical studies and follow-ups. Parsortix-harvested CTCs combined with the AR assay will help refine prostate cancer therapeutic assessments. The results could have substantial implications for over 130 active oncology clinical studies focused on androgen receptor assessments involving 30,000 participants.
Company Insights:
ANGLE’s Chief Executive Officer, Andrew Newland, expressed optimism regarding the project, noting, “This is further validation of ANGLE’s Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market. We anticipate that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials.”
Karen Miller, ANGLE’s Chief Scientific Officer, added, “We are delighted our expertise is being put to use in the isolation, harvest, and profiling of CTCs for androgen receptor investigation with the potential for ANGLE’s assays to be used in clinical trials.”
With this agreement in place, ANGLE plc and AstraZeneca have laid the groundwork for new strides in prostate cancer research and precision oncology, reinforcing the importance of liquid biopsy and CTC-based assays.